Longer Time to Chemotherapy Linked to Worse Outcomes in Triple-Negative Disease

Dr. Zaida Morante, medical oncologist at Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru, explains her research that found delaying chemotherapy for more than 30 days was associated with worse outcomes in women diagnosed with early-stage, triple-negative breast cancer. Triple-negative breast cancer is breast cancer that is estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative. Listen to the podcast to hear Dr. Morante explain: the design of the study which outcomes delaying chemotherapy affected possible explanations for why chemotherapy was delayed for some women